Last reviewed · How we verify
NCT02402998
Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
Phase 2 trial testing Eltrombopag in Primacy Immune Thrombocytopenia in 55 participants. Completed in 28 August 2019.
22 May 2018
Quick facts
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 55 |
| Start date | 24 February 2016 |
| Primary completion | 22 May 2018 |
| Estimated completion | 28 August 2019 |
| Sites | 14 locations across Italy |
Drugs / interventions tested
- Eltrombopag (ELTROMBOPAG) — full drug profile →
Conditions studied
- Primacy Immune Thrombocytopenia — all drugs for Primacy Immune Thrombocytopenia →
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto — full company profile →
Who can join
18 and older, any sex, with Primacy Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A clinical study to evaluate the efficacy of a drug called eltrombopag in adult patients affected of primary immune thrombocytopenia as first treatment to address the disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02402998
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eltrombopag
Trials testing the same drug.
- NCT07189910 — Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP · Phase 4 · not yet recruiting
- NCT07113743 — Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease · Phase 1, PHASE2 · enrolling by invitation
- NCT07093606 — Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura · NA · recruiting
- NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
- NCT05653219 — A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia · Phase 3 · active not recruiting
Other recruiting trials for Primacy Immune Thrombocytopenia
Currently open trials in the same condition.
- NCT07206823 — Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Th · NA · recruiting
Other Gruppo Italiano Malattie EMatologiche dell'Adulto trials
Trials by the same sponsor.
- NCT07356960 — Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world · not yet recruiting
- NCT07158294 — Identification of BCR::ABL1 Mutations by Digital PCR in CML · NA · not yet recruiting
- NCT07249606 — Momelotinib Effectiveness in Myelofibrosis · not yet recruiting
- NCT06880601 — Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma · Phase 2 · not yet recruiting
- NCT06657846 — HRQoL and Financial Toxicity in Patients With VEXAS Syndrome · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02402998 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Malattie EMatologiche dell'Adulto
- Last refreshed: 16 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02402998.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing